The first Caucasian patient with p.Val122Ile mutated-transthyretin cardiac amyloidosis treated with isolated heart transplantation

Enrico Ammirati, Nicola Marziliano, Claudia Vittori, Patrizia Pedrotti, Manuela A. Bramerio, Valentina Motta, Francesco Orsini, Silvio Veronese, Piera A. Merlini, Luigi Martinelli, Maria Frigerio

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Effective treatments for mutated transthyretin (TTR)-related cardiac amyloidosis are limited. Heart transplantation or combined liverheart transplantation are the most successful options, although results rely on underline mechanism and systemic nature of the disease. In this report, we present the first case of a Caucasian patient with the p.Val122Ile mutated TTR-related cardiac amyloidosis treated with heart transplantation due to this gene mutation frequent in Afro-Americans with a prevalent isolated heart involvement. The choice of isolated heart transplantation instead of combined heart and liver transplantations was based on (1) severe and progressive cardiac disease, (2) evidence of a gene mutation generally associated with isolated cardiac disease and (3) absence of relevant extra-cardiac involvement (with the possible exception of mild peripheral neuropathy). In any case, the very short post-transplant observation period of 10 months does not allow any conclusions on the long-term course of the presented strategy. Finally, it is the first European Caucasian family with the p.Val122Ile TTR mutation that has been described. Till now, very few Caucasian cases of p.Val122Ile mutated TTR-related cardiac amyloidosis have been reported. The patient and some members of his family also had mild peripheral neuropathy suggesting a regional phenotypic heterogeneity of European Caucasian TTR p.Val122Ile.

Original languageEnglish
Pages (from-to)113-117
Number of pages5
JournalAmyloid
Volume19
Issue number2
DOIs
Publication statusPublished - Jun 2012

Fingerprint

Prealbumin
Heart Transplantation
Amyloidosis
Peripheral Nervous System Diseases
Mutation
Heart Diseases
Liver Transplantation
Genes
Transplantation
Observation
Amyloidosis, Hereditary, Transthyretin-Related
Transplants

Keywords

  • Amyloidosis
  • Heart failure
  • Heart transplantation
  • Transthyretin
  • Val122Ile mutation

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Ammirati, E., Marziliano, N., Vittori, C., Pedrotti, P., Bramerio, M. A., Motta, V., ... Frigerio, M. (2012). The first Caucasian patient with p.Val122Ile mutated-transthyretin cardiac amyloidosis treated with isolated heart transplantation. Amyloid, 19(2), 113-117. https://doi.org/10.3109/13506129.2012.666509

The first Caucasian patient with p.Val122Ile mutated-transthyretin cardiac amyloidosis treated with isolated heart transplantation. / Ammirati, Enrico; Marziliano, Nicola; Vittori, Claudia; Pedrotti, Patrizia; Bramerio, Manuela A.; Motta, Valentina; Orsini, Francesco; Veronese, Silvio; Merlini, Piera A.; Martinelli, Luigi; Frigerio, Maria.

In: Amyloid, Vol. 19, No. 2, 06.2012, p. 113-117.

Research output: Contribution to journalArticle

Ammirati, E, Marziliano, N, Vittori, C, Pedrotti, P, Bramerio, MA, Motta, V, Orsini, F, Veronese, S, Merlini, PA, Martinelli, L & Frigerio, M 2012, 'The first Caucasian patient with p.Val122Ile mutated-transthyretin cardiac amyloidosis treated with isolated heart transplantation', Amyloid, vol. 19, no. 2, pp. 113-117. https://doi.org/10.3109/13506129.2012.666509
Ammirati, Enrico ; Marziliano, Nicola ; Vittori, Claudia ; Pedrotti, Patrizia ; Bramerio, Manuela A. ; Motta, Valentina ; Orsini, Francesco ; Veronese, Silvio ; Merlini, Piera A. ; Martinelli, Luigi ; Frigerio, Maria. / The first Caucasian patient with p.Val122Ile mutated-transthyretin cardiac amyloidosis treated with isolated heart transplantation. In: Amyloid. 2012 ; Vol. 19, No. 2. pp. 113-117.
@article{dfadc70e65e249caae00d57302f94185,
title = "The first Caucasian patient with p.Val122Ile mutated-transthyretin cardiac amyloidosis treated with isolated heart transplantation",
abstract = "Effective treatments for mutated transthyretin (TTR)-related cardiac amyloidosis are limited. Heart transplantation or combined liverheart transplantation are the most successful options, although results rely on underline mechanism and systemic nature of the disease. In this report, we present the first case of a Caucasian patient with the p.Val122Ile mutated TTR-related cardiac amyloidosis treated with heart transplantation due to this gene mutation frequent in Afro-Americans with a prevalent isolated heart involvement. The choice of isolated heart transplantation instead of combined heart and liver transplantations was based on (1) severe and progressive cardiac disease, (2) evidence of a gene mutation generally associated with isolated cardiac disease and (3) absence of relevant extra-cardiac involvement (with the possible exception of mild peripheral neuropathy). In any case, the very short post-transplant observation period of 10 months does not allow any conclusions on the long-term course of the presented strategy. Finally, it is the first European Caucasian family with the p.Val122Ile TTR mutation that has been described. Till now, very few Caucasian cases of p.Val122Ile mutated TTR-related cardiac amyloidosis have been reported. The patient and some members of his family also had mild peripheral neuropathy suggesting a regional phenotypic heterogeneity of European Caucasian TTR p.Val122Ile.",
keywords = "Amyloidosis, Heart failure, Heart transplantation, Transthyretin, Val122Ile mutation",
author = "Enrico Ammirati and Nicola Marziliano and Claudia Vittori and Patrizia Pedrotti and Bramerio, {Manuela A.} and Valentina Motta and Francesco Orsini and Silvio Veronese and Merlini, {Piera A.} and Luigi Martinelli and Maria Frigerio",
year = "2012",
month = "6",
doi = "10.3109/13506129.2012.666509",
language = "English",
volume = "19",
pages = "113--117",
journal = "Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis",
issn = "1350-6129",
publisher = "Taylor and Francis Ltd.",
number = "2",

}

TY - JOUR

T1 - The first Caucasian patient with p.Val122Ile mutated-transthyretin cardiac amyloidosis treated with isolated heart transplantation

AU - Ammirati, Enrico

AU - Marziliano, Nicola

AU - Vittori, Claudia

AU - Pedrotti, Patrizia

AU - Bramerio, Manuela A.

AU - Motta, Valentina

AU - Orsini, Francesco

AU - Veronese, Silvio

AU - Merlini, Piera A.

AU - Martinelli, Luigi

AU - Frigerio, Maria

PY - 2012/6

Y1 - 2012/6

N2 - Effective treatments for mutated transthyretin (TTR)-related cardiac amyloidosis are limited. Heart transplantation or combined liverheart transplantation are the most successful options, although results rely on underline mechanism and systemic nature of the disease. In this report, we present the first case of a Caucasian patient with the p.Val122Ile mutated TTR-related cardiac amyloidosis treated with heart transplantation due to this gene mutation frequent in Afro-Americans with a prevalent isolated heart involvement. The choice of isolated heart transplantation instead of combined heart and liver transplantations was based on (1) severe and progressive cardiac disease, (2) evidence of a gene mutation generally associated with isolated cardiac disease and (3) absence of relevant extra-cardiac involvement (with the possible exception of mild peripheral neuropathy). In any case, the very short post-transplant observation period of 10 months does not allow any conclusions on the long-term course of the presented strategy. Finally, it is the first European Caucasian family with the p.Val122Ile TTR mutation that has been described. Till now, very few Caucasian cases of p.Val122Ile mutated TTR-related cardiac amyloidosis have been reported. The patient and some members of his family also had mild peripheral neuropathy suggesting a regional phenotypic heterogeneity of European Caucasian TTR p.Val122Ile.

AB - Effective treatments for mutated transthyretin (TTR)-related cardiac amyloidosis are limited. Heart transplantation or combined liverheart transplantation are the most successful options, although results rely on underline mechanism and systemic nature of the disease. In this report, we present the first case of a Caucasian patient with the p.Val122Ile mutated TTR-related cardiac amyloidosis treated with heart transplantation due to this gene mutation frequent in Afro-Americans with a prevalent isolated heart involvement. The choice of isolated heart transplantation instead of combined heart and liver transplantations was based on (1) severe and progressive cardiac disease, (2) evidence of a gene mutation generally associated with isolated cardiac disease and (3) absence of relevant extra-cardiac involvement (with the possible exception of mild peripheral neuropathy). In any case, the very short post-transplant observation period of 10 months does not allow any conclusions on the long-term course of the presented strategy. Finally, it is the first European Caucasian family with the p.Val122Ile TTR mutation that has been described. Till now, very few Caucasian cases of p.Val122Ile mutated TTR-related cardiac amyloidosis have been reported. The patient and some members of his family also had mild peripheral neuropathy suggesting a regional phenotypic heterogeneity of European Caucasian TTR p.Val122Ile.

KW - Amyloidosis

KW - Heart failure

KW - Heart transplantation

KW - Transthyretin

KW - Val122Ile mutation

UR - http://www.scopus.com/inward/record.url?scp=84861635833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861635833&partnerID=8YFLogxK

U2 - 10.3109/13506129.2012.666509

DO - 10.3109/13506129.2012.666509

M3 - Article

C2 - 22449240

AN - SCOPUS:84861635833

VL - 19

SP - 113

EP - 117

JO - Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis

JF - Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis

SN - 1350-6129

IS - 2

ER -